Nexalin Takes Charge in TBI Advocacy Leadership
Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW) proudly announces its recent appointment as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This pivotal role underscores the company's deep commitment to advancing advocacy and research related to TBI. Alongside key policymakers and stakeholders in Washington, Nexalin aims to make significant strides in addressing this pressing health issue.
CEO's Commitment to TBI Solutions
Mark White, the CEO of Nexalin, expressed gratitude for the opportunity to lead this crucial initiative. "We are honored to be named Industry Co-Chair of the National TBI Registry Coalition," he stated. This role reflects our dedication to improving the lives of individuals impacted by traumatic brain injuries. As federal spending on TBI is expected to rise, we are working diligently with stakeholders to drive meaningful solutions for this underserved community.
Collaborative Research and Development
Nexalin's newfound leadership position ties into its ongoing research initiatives, notably a collaborative study with the University of California, San Diego (UCSD) and the San Diego Veterans Affairs (VA). This joint effort aims to explore innovative treatments specifically designed for veterans grappling with TBI. This research signifies a step towards finding effective therapies that are essential for those affected.
Strengthening Legislative Relationships
In addition to research initiatives, Nexalin has been actively engaging with legislators across Congress to fortify relationships with federal agencies. The company's aim is to enhance TBI care and support through legislative advocacy. Continued dialogue with key decision-makers is a critical part of their strategy moving forward.
About Nexalin Technology, Inc.
Nexalin is at the forefront of designing and developing cutting-edge neurostimulation products aimed at combating the growing mental health crisis globally. Their non-invasive and undetectable technology provides much-needed relief for individuals dealing with various mental health challenges. Utilizing bioelectronic medical technology, Nexalin focuses on addressing disorders connected deeper in the mid-brain, improving patient responses without adverse side effects.
Innovative Neurostimulation Devices
The company's products include the Nexalin Gen-2 15 milliamp neurostimulation device, which has received approvals in countries such as China, Brazil, and Oman. Nexalin leverages its expertise to develop next-generation devices that promise innovative treatments with a commitment to safety and efficacy.
Looking Ahead at TBI Advocacy
As Nexalin embarks on this leadership role, the company is poised to share further developments that arise from its initiatives. The commitment to improving care and finding effective treatments for traumatic brain injuries underscores Nexalin’s mission to make a meaningful impact in this critical field.
Frequently Asked Questions
What is the National TBI Registry Coalition?
The National TBI Registry Coalition is an organization focused on enhancing awareness, research, and treatment options for traumatic brain injuries.
What role does Nexalin play in the coalition?
Nexalin serves as the Industry Co-Chair, leading efforts to advocate for improved TBI care and treatment solutions.
How does Nexalin's technology work?
Nexalin's neurostimulation devices use bioelectronic medical technology to treat mental health disorders by stimulating specific regions in the brain.
What recent collaborations has Nexalin initiated?
Nexalin has partnered with UCSD and the San Diego VA to explore innovative treatment options for veterans suffering from TBI.
What are the future plans of Nexalin in TBI research?
Nexalin plans to continue working closely with legislators and stakeholders while advancing its research initiatives to improve care for TBI patients.
